基本情報
- 所属
- 日本獣医生命科学大学 獣医内科学研究室 講師
- 学位
- 博士(獣医学)(日本獣医生命科学大学)
- 研究者番号
- 80825216
- ORCID ID
https://orcid.org/0000-0001-9451-5854
- J-GLOBAL ID
- 201801016742323716
- researchmap会員ID
- B000290975
- 外部リンク
研究キーワード
31経歴
12-
2025年1月 - 現在
-
2024年4月 - 現在
-
2022年7月 - 現在
-
2022年4月 - 現在
-
2022年4月 - 現在
学歴
2-
2010年4月 - 2014年3月
-
2004年4月 - 2010年3月
委員歴
6-
2023年1月 - 現在
-
2021年7月 - 現在
-
2021年7月 - 現在
受賞
11論文
57-
Regenerative therapy 28 301-313 2025年3月 査読有りINTRODUCTION: Intestinal lymphoma may be latent in some dogs with chronic inflammatory enteropathy. Mesenchymal stromal cells (MSCs) have potential therapeutic applications for refractory chronic inflammatory enteropathy, but their impact on the development of potential intestinal lymphomas has not yet been evaluated. Therefore, this study was performed to investigate the effect of canine adipose-derived MSCs (cADSCs) on the growth of canine lymphoma cell lines to assess the safety of MSC-based therapy in terms of pro- and anti-tumorigenic effects. METHODS: CADSCs were co-cultured with canine lymphoma/leukemia cell lines of various lineages, with or without cell-to-cell contact, to evaluate their effects on proliferation, apoptosis, and cell cycle progression in vitro. Additionally, a bioluminescent canine lymphoma cell line, established through firefly luciferase transduction, was co-injected with varying doses of cADSCs into immunocompromised mice. The growth of canine lymphoma cells was monitored over time in vivo using bioluminescence imaging. RESULTS: CADSCs inhibited the proliferation of all canine lymphoma/leukemia cell lines in a dose-dependent manner in vitro, under conditions allowing cell-to-cell contact. This inhibition occurred via the induction of apoptosis, G0/G1 phase cell cycle arrest, or both mechanisms. However, these effects were lost when the cells were physically separated using Transwell inserts. In xenotransplantation mouse models, cADSCs dose-dependently inhibited canine lymphoma cell growth and lung metastasis, as indicated by reduced bioluminescence signals. CONCLUSIONS: This study has demonstrated for the first time that cADSCs inhibit the growth of different lineages of canine lymphoma/leukemia cells both in vitro and in vivo. These findings suggest that MSC-based cell therapy could potentially be applied to canine chronic inflammatory enteropathy without increasing the risk of promoting the growth of latent intestinal lymphomas.
-
Frontiers in Veterinary Science 11 2024年8月8日 査読有りIntroduction The therapeutic efficacy of mesenchymal stromal cells (MSCs) in inflammatory bowel disease is not completely known and is not consistent. Priming with inflammatory cytokines has been proposed to adapt MSCs to an inflammatory environment to have them ready to counteract it, but may have undesirable effects on MSCs, such as increased immunogenicity. In this study, we hypothesized that priming MSCs with inflamed intestinal tissue would more effectively enhance their therapeutic effect on intestinal inflammation. Methods The capacity of canine adipose-derived MSCs (cADSCs) primed with colon tissue homogenates from mice with experimentally induced colitis or a combination of tumor necrosis factor-α and interferon-γ to inhibit T-cell proliferation was analyzed, along with their own apoptosis, proliferation, cell surface marker expression, and transcriptome. In addition, colitis mice were treated with the primed cADSCs to assess colitis severity and immune cell profile. Results Priming with cytokines induced apoptosis, decreased cell proliferation, and major histocompatibility complex-II gene expression in cADSCs, but these adverse effects were mild or absent with colitis-tissue priming. cADSCs primed with colitis tissue reduced the severity of colitis via the induction of M2 macrophages and T-regulatory cells and suppression of T-helper (Th)1/Th17-cell responses, and their effects were comparable to those of cytokine-primed cells. Discussion Our results emphasize the importance of the activation of MSCs by the appropriate microenvironment to maximize their therapeutic effect.
-
Journal of Veterinary Internal Medicine 2024年7月 査読有り筆頭著者責任著者
-
Biology 2024年4月30日 査読有り筆頭著者責任著者
-
International Journal of Molecular Sciences 2023年12月14日 査読有り
MISC
96-
VETERINARY BOARD 7(1) 110-111 2025年1月 招待有り最終著者責任著者
書籍等出版物
20講演・口頭発表等
240担当経験のある科目(授業)
18-
2024年4月 - 現在獣医内科学各論Ⅷ(獣医循環器病学アドバンス)(獣医学科5年次) (日本獣医生命科学大学)
-
2023年4月 - 現在獣医内科学各論Ⅱ(獣医循環器病学コア)(獣医学科4年次) (日本獣医生命科学大学)
-
2023年4月 - 現在獣医内科学各論Ⅲ(獣医画像診断学)(獣医学科4年次) (日本獣医生命科学大学)
-
2022年4月 - 現在獣医救急医療学(獣医学科5年次) (日本獣医生命科学大学)
-
2019年4月 - 現在共済実習(獣医学科5年次) (日本獣医生命科学大学)
所属学協会
9-
2023年 - 現在
-
2018年 - 現在
共同研究・競争的資金等の研究課題
11-
アニコム損害保険株式会社 共同研究 2022年9月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2022年4月 - 2025年3月
-
日本獣医生命科学大学 令和5年度大学間連携等による共同研究 2023年9月 - 2024年3月
-
日本獣医生命科学大学 2023年度特色ある研究プロジェクト 2023年8月 - 2024年3月
-
令和4 年度大学間連携等による共同研究 2022年9月 - 2023年3月
学術貢献活動
18-
企画立案・運営等, 監修, 審査・評価, 査読Animals, Ryohei Suzuki 2025年3月